<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1082">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852812</url>
  </required_header>
  <id_info>
    <org_study_id>0476-520</org_study_id>
    <secondary_id>132233</secondary_id>
    <nct_id>NCT01852812</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)</brief_title>
  <official_title>A Phase III, Open-Label Clinical Trial to Study the Safety and Pharmacokinetics of MK-0476 in Japanese Pediatric Subjects Aged 1 to 15 Years Old With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and pharmacokinetics of montelukast (MK-0476) in the
      treatment of Japanese pediatric participants with perennial allergic rhinitis (PAR). The
      primary hypothesis of this study is that montelukast oral granules (OG) and chewable tablets
      (CT) provide appropriate exposure to montelukast in Japanese pediatric participants with
      PAR.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience at Least One Adverse Event (AE)</measure>
    <time_frame>Up to 14 days after last dose of study drug (Up to 14 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a pre-existing condition that is temporally associated with the use of study drug is also an AE. Participants were monitored for the occurrence of AEs for up to 14 days after last dose of study drug (up to a total of 14 weeks). AEs were reported based on the dose of study drug participants received.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinue Study Drug Due to an AE</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a pre-existing condition that is temporally associated with the use of study drug is also an AE. Discontinuations due to an AE were reported based on the dose of study drug participants received.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Time-Concentration Curve (AUC 0-∞) of Montelukast CT and Montelukast OG</measure>
    <time_frame>Up to Day 28 after first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples for pharmacokinetic (PK) assessments were collected at either 1 hour (h) or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Montelukast CT and Montelukast OG</measure>
    <time_frame>Up to Day 28 after first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of Montelukast CT and Montelukast OG</measure>
    <time_frame>Up to Day 28 after first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Elimination Half-life (t1/2) of Montelukast CT and Montelukast OG</measure>
    <time_frame>Up to Day 28 after first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Montelukast 4 mg OG/1-5 year olds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive montelukast 4 mg OG in one sachet orally (PO) once daily (QD) at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast 5 mg CT/6-9 year olds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast 5 mg CT/10-15 year olds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast Oral Granules (OG)</intervention_name>
    <description>Montelukast 4 mg in one sachet</description>
    <arm_group_label>Montelukast 4 mg OG/1-5 year olds</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast Chewable Tablets (CT)</intervention_name>
    <description>Montelukast 5 mg in one tablet</description>
    <arm_group_label>Montelukast 5 mg CT/6-9 year olds</arm_group_label>
    <arm_group_label>Montelukast 5 mg CT/10-15 year olds</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight ≥8 kg

          -  Diagnosis of PAR and has symptoms of PAR at Visit 1

        Exclusion Criteria:

          -  Past or present medical history of asthma

          -  Diagosis of acute rhinitis, simple rhinitis, rhinitis congestive, rhinitis atrophic,
             sinusitis with purulent nasal discharge, rhinitis medicamentosa or nonallergic
             rhinitis (e.g. vasomotor rhinitis, eosinophilic rhinitis)

          -  Started hyposensitization therapy or non-specific immunotherapy within 6 months prior
             to Visit 1

          -  Medical history of inferior concha mucosal resection, submucous resection of inferior
             turbinates or other surgery aimed at reduction and/or modulation of nasal mucosa
             (including electrocoagulation, cryoextraction or application of trichloroacetic acid)

          -  Clinically significant, active disease of the cardiovascular or hematologic systems
             or uncontrolled hypertension (1 to 5 year olds: &gt;120/70 mmHg; 6 to 9 year olds:
             &gt;130/80 mmHg; 10 to 15 year olds: &gt;140/85 mmHg)

          -  Medical history of stunted growth

          -  Serious drug allergy

          -  Treated with other clinical study drug within 3 months prior to Visit 1
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 29, 2015</lastchanged_date>
  <firstreceived_date>May 9, 2013</firstreceived_date>
  <firstreceived_results_date>September 25, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Montelukast 4 mg OG/1-5 Year Olds</title>
          <description>Participants receive montelukast 4 mg oral granules (OG) in one sachet orally (PO) once daily (QD) at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)</description>
        </group>
        <group group_id="P2">
          <title>Montelukast 5 mg CT/6-9 Year Olds</title>
          <description>Participants receive montelukast 5 mg chewable tablets (CT) in one tablet PO QD at bed time for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Montelukast 5 mg CT/10-15 Year Olds</title>
          <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Montelukast 4 mg OG/1-5 Year Olds</title>
          <description>Participants receive montelukast 4 mg OG in one sachet PO QD at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)</description>
        </group>
        <group group_id="B2">
          <title>Montelukast 5 mg CT/6-9 Year Olds</title>
          <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Montelukast 5 mg CT/10-15 Year Olds</title>
          <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="18"/>
                <measurement group_id="B4" value="87"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3.61" spread="1.4"/>
                <measurement group_id="B2" value="7.78" spread="1.3"/>
                <measurement group_id="B3" value="11.3" spread="1.0"/>
                <measurement group_id="B4" value="6.07" spread="3.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="37"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="13"/>
                <measurement group_id="B4" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience at Least One Adverse Event (AE)</title>
        <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a pre-existing condition that is temporally associated with the use of study drug is also an AE. Participants were monitored for the occurrence of AEs for up to 14 days after last dose of study drug (up to a total of 14 weeks). AEs were reported based on the dose of study drug participants received.</description>
        <time_frame>Up to 14 days after last dose of study drug (Up to 14 weeks)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The All Subjects as Treated (ASaT) population consisted of all participants who received at least one dose of study drug. Data from the two montelukast 5 mg CT groups (6-9 year olds and 10-15 year olds) were pooled for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 4 mg OG/1-5 Year Olds</title>
            <description>Participants receive montelukast 4 mg OG in one sachet PO QD at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 5 mg CT/6-15 Year Olds</title>
            <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Who Experience at Least One Adverse Event (AE)</title>
            <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a pre-existing condition that is temporally associated with the use of study drug is also an AE. Participants were monitored for the occurrence of AEs for up to 14 days after last dose of study drug (up to a total of 14 weeks). AEs were reported based on the dose of study drug participants received.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="74.5"/>
                  <measurement group_id="O2" value="55.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinue Study Drug Due to an AE</title>
        <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a pre-existing condition that is temporally associated with the use of study drug is also an AE. Discontinuations due to an AE were reported based on the dose of study drug participants received.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The ASaT population consisted of all participants who received at least one dose of study drug. Data from the two montelukast 5 mg CT groups (6-9 year olds and 10-15 year olds) were pooled for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 4 mg OG/1-5 Year Olds</title>
            <description>Participants receive montelukast 4 mg OG in one sachet PO QD at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 5 mg CT/6-15 Year Olds</title>
            <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Who Discontinue Study Drug Due to an AE</title>
            <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a pre-existing condition that is temporally associated with the use of study drug is also an AE. Discontinuations due to an AE were reported based on the dose of study drug participants received.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="2.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Time-Concentration Curve (AUC 0-∞) of Montelukast CT and Montelukast OG</title>
        <description>Blood samples for pharmacokinetic (PK) assessments were collected at either 1 hour (h) or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
        <time_frame>Up to Day 28 after first dose of study drug</time_frame>
        <safety_issue>No</safety_issue>
        <population>The All Subjects Pharmacokinetically Evaluable (ASPE) population consisted of all participants from the ASaT population who had an evaluable assessement for this PK parameter and did not have any protocol violation which would interfere with this PK parameter. Data for PK assessments were reported by dose of study drug received and age group.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 4 mg OG/1-5 Year Olds</title>
            <description>Participants receive montelukast 4 mg OG in one sachet PO QD at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 5 mg CT/6-9 Year Olds</title>
            <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 5 mg CT/10-15 Year Olds</title>
            <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Time-Concentration Curve (AUC 0-∞) of Montelukast CT and Montelukast OG</title>
            <description>Blood samples for pharmacokinetic (PK) assessments were collected at either 1 hour (h) or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
            <units>h*ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4300" spread="800"/>
                  <measurement group_id="O2" value="4350" spread="760"/>
                  <measurement group_id="O3" value="3500" spread="620"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Montelukast CT and Montelukast OG</title>
        <description>Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
        <time_frame>Up to Day 28 after first dose of study drug</time_frame>
        <safety_issue>No</safety_issue>
        <population>The ASPE population consisted of all participants from the ASaT population who had an evaluable assessement for this PK parameter and did not have any protocol violation which would interfere with this PK parameter. Data for PK assessments were reported by dose of study drug received and age group.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 4 mg OG/1-5 Year Olds</title>
            <description>Participants receive montelukast 4 mg OG in one sachet PO QD at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 5 mg CT/6-9 Year Olds</title>
            <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 5 mg CT/10-15 Year Olds</title>
            <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Plasma Concentration (Cmax) of Montelukast CT and Montelukast OG</title>
            <description>Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
            <units>ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="510" spread="84"/>
                  <measurement group_id="O2" value="438" spread="82"/>
                  <measurement group_id="O3" value="344" spread="61"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Cmax (Tmax) of Montelukast CT and Montelukast OG</title>
        <description>Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
        <time_frame>Up to Day 28 after first dose of study drug</time_frame>
        <safety_issue>No</safety_issue>
        <population>The ASPE population consisted of all participants from the ASaT population who had an evaluable assessement for this PK parameter and did not have any protocol violation which would interfere with this PK parameter. Data for PK assessments were reported by dose of study drug received and age group.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 4 mg OG/1-5 Year Olds</title>
            <description>Participants receive montelukast 4 mg OG in one sachet PO QD at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 5 mg CT/6-9 Year Olds</title>
            <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 5 mg CT/10-15 Year Olds</title>
            <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Cmax (Tmax) of Montelukast CT and Montelukast OG</title>
            <description>Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
            <units>Hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.74" spread="0.60"/>
                  <measurement group_id="O2" value="3.55" spread="0.71"/>
                  <measurement group_id="O3" value="3.65" spread="0.60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Elimination Half-life (t1/2) of Montelukast CT and Montelukast OG</title>
        <description>Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
        <time_frame>Up to Day 28 after first dose of study drug</time_frame>
        <safety_issue>No</safety_issue>
        <population>The ASPE population consisted of all participants from the ASaT population who had an evaluable assessement for this PK parameter and did not have any protocol violation which would interfere with this PK parameter. Data for PK assessments were reported by dose of study drug received and age group.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 4 mg OG/1-5 Year Olds</title>
            <description>Participants receive montelukast 4 mg OG in one sachet PO QD at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 5 mg CT/6-9 Year Olds</title>
            <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 5 mg CT/10-15 Year Olds</title>
            <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apparent Elimination Half-life (t1/2) of Montelukast CT and Montelukast OG</title>
            <description>Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.</description>
            <units>Hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.27" spread="0.56"/>
                  <measurement group_id="O2" value="2.01" spread="0.75"/>
                  <measurement group_id="O3" value="2.08" spread="0.66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after last dose of study drug (Up to 14 weeks)</time_frame>
      <desc>The ASaT population consisted of all participants who received at least one dose of study drug. AEs were reported based on the dose of study drug participants received. Data from the two montelukast 5 mg CT groups (6-9 year olds and 10-15 year olds) were pooled for safety analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Montelukast 4 mg OG/1-5 Year Olds</title>
          <description>Participants receive montelukast 4 mg OG in one sachet PO QD at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)</description>
        </group>
        <group group_id="E2">
          <title>Montelukast 5 mg CT/6-15 Year Olds</title>
          <description>Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="22" subjects_at_risk="51"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
